Search
Periciazine
go.drugbank.com/drugs/DB01608ApprovedIt is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. … It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected.
Parachlorophenol
go.drugbank.com/drugs/DB13154ApprovedWithdrawnP-chlorophenol is a white crystals with a strong phenol odor. Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigationalin thermo-regulation. … [L53798] Later the same year, it was approved in the US for the same indication. [L54216]
Synonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.Oseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalgenerally no benefit in use beyond 48 hours for healthy, low-risk individuals as influenza is a self-limiting illness. … [A179962, A179965, A179968] Due to the risk of adverse effects such as nausea, vomiting, psychiatric effects and renal adverse events in adults and vomiting in children, the harms are generally considered
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedNisoldipine may be used in alone or in combination with other agents in the management of hypertension. … Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
International brands: Di Yi Xin, Ji Ni Le ErSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalfound to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigationalNemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.
Sagopilone
go.drugbank.com/drugs/DB12391Investigationalmultidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo. … It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer.
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. … Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.
Selexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalcirculation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary